about
High resolution melting for mutation scanning of TP53 exons 5-8Induction of apoptosis by cytoplasmically localized wild-type p53 and the S121F mutant super p53Tumor antigen LRRC15 impedes adenoviral infection: implications for virus-based cancer therapyCancer immunoediting from immune surveillance to immune escapeMutant p53: Multiple Mechanisms Define Biologic Activity in Cancerp53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.Establishment and characterization of a highly tumourigenic and cancer stem cell enriched pancreatic cancer cell line as a well defined model systemTransient transfection of a wild-type p53 gene triggers resveratrol-induced apoptosis in cancer cellsFunctional activation of mutant p53V172F by platinum analogs in cisplatin-resistant human tumor cells is dependent on serine-20 phosphorylationMutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.The p53 tumor suppressor-like protein nvp63 mediates selective germ cell death in the sea anemone Nematostella vectensisSIRT1 undergoes alternative splicing in a novel auto-regulatory loop with p53.TP53 mutations in Korean patients with non-small cell lung cancer.Assessing the value of CAN-gene mutations using MALDI-TOF MS.p53 Gene repair with zinc finger nucleases optimised by yeast 1-hybrid and validated by Solexa sequencing.COLD-PCR enrichment of rare cancer mutations prior to targeted amplicon resequencing.A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.The antagonism between MCT-1 and p53 affects the tumorigenic outcomes.A functional polymorphism T309G in MDM2 gene promoter, intensified by Helicobacter pylori lipopolysaccharide, is associated with both an increased susceptibility and poor prognosis of gastric carcinoma in Chinese patients.BCCIP as a prognostic marker for radiotherapy of laryngeal cancer.Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stressPrognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity.Manganese superoxide dismutase is a p53-regulated gene that switches cancers between early and advanced stagesTP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment.A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo.The proline TP53 variant stimulates likely lymphangiogenesis in an orthotopic mouse model of pancreatic cancer.Reversine suppresses oral squamous cell carcinoma via cell cycle arrest and concomitantly apoptosis and autophagyReticulon Protein-1C: A New Hope in the Treatment of Different Neuronal Diseases.Mutant p53: one name, many proteins.Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression.p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling.Transcriptional functionality of germ line p53 mutants influences cancer phenotype.Molecular classification and biomarker discovery in papillary thyroid carcinoma.ARF-BP1 as a potential therapeutic targetTumor regression by phenethyl isothiocyanate involves DDB2.Heritability of DNA-damage-induced apoptosis and its relationship with age in lymphocytes from female twins.Intercellular and intracellular signaling pathways mediating ionizing radiation-induced bystander effects.p53 alterations in human cancer: more questions than answers.
P2860
Q21260416-CF3DB2B7-99D0-416E-B0FD-0C29228925B9Q24293008-8F248E9B-9C67-4913-A91B-3D5A862E6E7AQ24316301-DFCCBD75-381D-43A2-B5ED-37B80F3F0DC2Q24655415-ADA90146-F0B8-4102-81D6-EA15742BB8B9Q26776020-9270522D-7F57-4169-98DF-4CB21688B4CAQ27851827-AF8022D8-9431-470E-BD08-1D9CD9454832Q28485145-36DE909C-879B-43B6-A2C2-4C5181DF58E1Q28485155-56D30EE2-0CB1-4315-9940-4E98AF12F500Q29248201-CF5232C8-063F-436A-BC2C-A99D5E8FFE49Q30354662-24E8ED75-4D96-4156-AB4C-CE70798D682EQ30416701-5F642054-15B4-49C9-8BEF-F62C014C7BDEQ33298587-87329784-166C-4A34-AD31-17AD5EC3FC4BQ33727892-911AE770-723E-4588-BCC7-8C7203B06078Q33807219-43E6403E-DA4C-4C74-9400-E1122095E4EEQ33938193-87C48C91-B051-4E63-9B06-5B6EE91978F0Q33939746-C23297FA-9C63-44D4-96DB-29878A2F51D3Q34109720-59A947E7-EE12-40BD-BDCE-452873633B86Q34148472-50776B6A-E5A7-44E6-8EF9-E7D924DEA1E2Q34481803-4404E78E-00BA-400A-AE95-BD3CEA735147Q34626391-A509334B-E7CF-4DE1-B06A-8366A5D606EEQ34820388-95802329-8E19-4622-99EE-98E4F2F3AA0CQ35103873-900A1C9A-4E80-4B76-8C39-D6E9F77D5EC9Q35169579-353A3538-017D-4D5A-9440-E37D9686DA74Q35250855-735985B9-D19E-4727-9696-3A826E39E546Q35500990-967F4150-2E97-4D1D-8B8E-248B0143F2D6Q35646576-72D37F36-B18C-406B-AAF1-576643066D62Q35664079-4EDFB731-3658-454D-AE86-2177874B4EB3Q35681952-7C67426D-0D49-479B-B8EC-FA245843A838Q35822375-D13A3F99-9313-4D46-AC76-5BC818FE50F8Q36010989-393C0D97-472A-471A-ACB2-09A975431AB0Q36070574-D96003A6-1EB1-4158-BE14-C688DC47C610Q36095652-D6B098C4-4538-449E-8A60-477BDE94D149Q36116766-8C6980C1-6861-4699-9EF3-467FE55F00A7Q36248891-BF8483FB-1D31-4489-9766-74475B73B342Q36299916-38758074-8F42-4010-98F1-6632EBC4E0D6Q36461587-A3F5258E-09AE-4FAB-BCB5-28210EA2D5D6Q36608692-990553E1-F428-4148-B04A-6EA754DB0112Q36612213-DDB57568-238A-41E9-806F-29022EF6938CQ36747077-072D8D7C-51D1-468E-B2DA-9B06DB7C2C9EQ36777320-835CB8F2-72A8-47AA-885D-26E814DE5CFF
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
p53 mutation heterogeneity in cancer.
@ast
p53 mutation heterogeneity in cancer.
@en
type
label
p53 mutation heterogeneity in cancer.
@ast
p53 mutation heterogeneity in cancer.
@en
prefLabel
p53 mutation heterogeneity in cancer.
@ast
p53 mutation heterogeneity in cancer.
@en
P1476
p53 mutation heterogeneity in cancer.
@en
P2093
P304
P356
10.1016/J.BBRC.2005.03.190
P407
P577
2005-06-01T00:00:00Z